Abstract 199P
Background
To evaluate the efficacy and safety of Endostar combined with concurrent chemoradiothery(CCRT) in patients with locally advanced esophageal squamous cell carcinoma(ESCC).
Methods
From May 2017 to February 2021, 90 patients with unresectable thoracic ESCC, clinical staged as IB to IVB disease based on the 8th edition of the American Joint Committee on Cancer (stage IVB:only metastasis to supraclavicular/celiac lymph nodes) and local recurrence, were enrolled and randomly allocated in Endostar plus concurrent chemoradiothery (CCRT)(intervention group; n=44) and concurrent chemoradiothery (CCRT)(control group; n=46). Five or six cycles of Endostar (7.5mg/m2/24h ×120h, 7 days/cycle) were delivered in intervention group. The primary endpoint was overall survival(OS). The secondary end-points were progression-free survival (PFS), 1-year and 2-year overall survival rate and adverse events (AE).
Results
The median age was 63(interquartile range, 50-77) years in intervention group and 65(interquartile range, 52-79) years in control group. A total of 67 patients (74%) had stage III and IV disease. The Endostar-combined group had a significant higher complete response rate(ORR) than the control group((80% vs. 63.8%; P=0.084). Survival patients had a median follow-up of 51.5 months(interquartile range: 48.2-54.8 months). The median overall survival were 16.7m in Endostar-combined group and 12.8m in control group, respectively(p=0.054). The Endostar-combined group had a significantly higher 5-year overall survival rate(13.6% vs 0%; p=0.014). The were no significant differences in the incidence of grade 3 or higher toxic effects between the intervention group and control group(P>0.05).
Conclusions
This trial shows the combination of Endostar with concurrent chemoradiotheray (CCRT) was tolerable and provided higher ORR and 5-year overall survival rate over concurrent chemoradiothery (CCRT), and is very likely to provide promising survival benefit in patients with locally advanced ESCC.
Clinical trial identification
ChiCTR-IPR-16009926.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract